Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | XDH | P47989 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.40 |
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL839641 | 0.83 | KMT2A (0.48) | KMT2AALDH1A1NPSR1KDM4EMEN1 | |
| SCHEMBL838742 | 0.81 | KMT2A (0.50) | KMT2AALDH1A1NPSR1KDM4EMEN1 | |
| SCHEMBL840161 | 0.80 | KMT2A (0.53) | KMT2AALDH1A1NPSR1KDM4EMEN1 | |
| SCHEMBL14477279 | 0.80 | KMT2A (0.45) | KMT2AALDH1A1NPSR1KDM4EMEN1 | |
| SCHEMBL1457396 | 0.79 | KMT2A (0.62) | KMT2AALDH1A1NPSR1KDM4EMEN1 | |
| SCHEMBL824637 | 0.78 | KMT2A (0.54) | KMT2AALDH1A1NPSR1KDM4EMEN1 | |
| SCHEMBL1457376 | 0.78 | KMT2A (0.57) | KMT2AALDH1A1NPSR1KDM4EMEN1 | |
| SCHEMBL1456326 | 0.75 | KMT2A (0.58) | KMT2AALDH1A1NPSR1KDM4EMEN1 | |
| SCHEMBL824888 | 0.75 | PLAUR (0.52) | KMT2AALDH1A1NPSR1KDM4EMEN1 | |
| SCHEMBL8046923 | 0.73 | KMT2A (0.56) | KMT2AALDH1A1NPSR1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143263-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2012-03-27 | — | — | US | disclosed |
| US-8143263-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2012-03-27 | — | — | US | disclosed |
| US-8143263-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2012-03-27 | — | — | US | disclosed |
| CN-102171213-A | Pyrazolo [3, 4] pyrimidin-4-yl derivatives and their uses to treat diabetes and obesity | ASTRAZENECA AB | 2011-08-31 | — | — | CN | disclosed |
| EP-2324028-A2 | THERAPEUTIC AGENTS 414 | AstraZeneca AB (SE) | 2011-05-25 | — | — | EP | disclosed |
| US-20100093757-A1 | THERAPEUTIC AGENTS 414 | ASTRAZENECA AB (SE) | 2010-04-15 | — | — | US | disclosed |
| US-20100093757-A1 | THERAPEUTIC AGENTS 414 | ASTRAZENECA AB (SE) | 2010-04-15 | — | — | US | disclosed |
| US-20100093757-A1 | THERAPEUTIC AGENTS 414 | ASTRAZENECA AB (SE) | 2010-04-15 | — | — | US | disclosed |
| WO-2010015849-A2 | THERAPEUTIC AGENTS 414 | ASTRAZENECA AB (SE) | 2010-02-11 | — | — | WO | disclosed |
| WO-2010015849-A2 | THERAPEUTIC AGENTS 414 | ASTRAZENECA AB (SE) | 2010-02-11 | — | — | WO | disclosed |
| US-7615558-B2 | 6-arylmethylprazolo[3,4-d]pyrimidines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093757-A1 | THERAPEUTIC AGENTS 414 | GCK, GCKR, GPR119 | KMT2A 4136/4885ALDH1A1 1918/4885NPSR1 2666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.